Brokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Target Price at $36.20

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has earned an average recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $36.20.

Several analysts recently issued reports on the company. JPMorgan Chase & Co. increased their price objective on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a report on Thursday, November 21st. Scotiabank cut their price objective on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. Citigroup increased their price objective on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, November 19th. The Goldman Sachs Group increased their price objective on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, HC Wainwright restated a “buy” rating and set a $51.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, December 10th.

Insider Transactions at Syndax Pharmaceuticals

In other news, insider Neil Gallagher sold 4,618 shares of Syndax Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $71,579.00. Following the transaction, the insider now directly owns 85,095 shares in the company, valued at approximately $1,318,972.50. The trade was a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Michael A. Metzger sold 13,288 shares of Syndax Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.00. Following the completion of the transaction, the chief executive officer now owns 300,121 shares in the company, valued at $4,651,875.50. The trade was a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,683 shares of company stock worth $336,087. Company insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Values First Advisors Inc. bought a new position in shares of Syndax Pharmaceuticals in the third quarter worth about $30,000. R Squared Ltd acquired a new stake in Syndax Pharmaceuticals during the fourth quarter worth about $26,000. Quantbot Technologies LP acquired a new stake in Syndax Pharmaceuticals during the third quarter worth about $49,000. Mirae Asset Global Investments Co. Ltd. grew its position in Syndax Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after buying an additional 541 shares in the last quarter. Finally, Virtus ETF Advisers LLC grew its position in Syndax Pharmaceuticals by 18.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock worth $70,000 after buying an additional 827 shares in the last quarter.

Syndax Pharmaceuticals Trading Up 2.4 %

Shares of NASDAQ:SNDX opened at $16.38 on Friday. Syndax Pharmaceuticals has a 1 year low of $12.06 and a 1 year high of $25.34. The business has a fifty day simple moving average of $13.97 and a 200 day simple moving average of $16.95. The firm has a market cap of $1.40 billion, a price-to-earnings ratio of -4.51 and a beta of 0.90.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).